TY - CHAP M1 - Book, Section TI - Pigmentary Conditions A1 - Usatine, Richard P. A1 - Sabella, Camille A1 - Smith, Mindy Ann A1 - Mayeaux, E.J. A1 - Chumley, Heidi S. A1 - Appachi, Elumalai PY - 2015 T2 - The Color Atlas of Pediatrics AB - References1Taïeb A Picardo M; VETF Members: The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20(1):27–35.17250545[PubMed: ]2Njoo MD Westerhof W. Vitiligo: pathogenesis and treatment. Am J Clin Dermatol. 2001;2(3):167–181.3KrügerC SchallreuterKU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012 Mar 27. doi: 10.1111/j.1365-4632. 2011.05377.x. [Epub ahead of print].4Karaca N Ozturk G Gerceker BT et al. TLR2 and TLR4 gene polymorphisms in Turkish vitiligo patients. J Eur Acad Dermatol Venereol. 2012 Mar 16. doi: 10.1111/j.1468-3083. 2012.04514.x. [Epub ahead of print].5Alghamdi KM Kumar A Taïeb A Ezzedine K. Assessment methods for the evaluation of vitiligo. J Eur Acad Dermatol Venereol. 2012 Mar 15. doi: 10.1111/j.1468-3083. 2012.04505.x. [Epub ahead of print].6Schallreuter KU Lemke R Brandt O et al. Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology. 1994;188(4):269–275.8193398[PubMed: ]7Hegedüs L Heidenheim M Gervil M et al. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol. 1994;74(2):120–123.7911617[PubMed: ]8Rogosic´ V Bojic´ L Puizina-Ivic´ N et al. Vitiligo and glaucoma – an association or a coincidence? A pilot study. Acta Dermatovenerol Croat. 2010;18(1):21–26.20361884[PubMed: ]9Barona MI Arrunátegui A Falabella R Alzate A. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol. 1995;33(4):621–625.7673496[PubMed: ]10Hacker SM. Common disorders of pigmentation: When are more than cosmetic cover-ups required? Postgrad Med. 1996;99(6):177–186.8668630[PubMed: ]11Bacigalupi RM Postolova A Davis RS. Evidence-based, non-surgical treatments for vitiligo: a review. Am J Clin Dermatol. 2012 Mar 16. doi: 10.2165/11630540-000000000-00000. [Epub ahead of print].12Hossani-Madani AR, Halder RM. Topical treatment and combination approaches for vitiligo: new insights, new developments. G Ital Dermatol Venereol. 2010;145(1):57–78.20197746[PubMed: ]13Kwinter J Pelletier J Khambalia A Pope E. High-potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol. 2007;56(2):236–241.17224367[PubMed: ]14Forschner T Buchholtz S Stockfleth E. Current state of vitiligo therapy—evidence-based analysis of the literature. J Dtsch Dermatol Ges. 2007;5(6):467–475.17537039[PubMed: ]15Alghamdi KM Khurrum H Taieb A Ezzedine K. Treatment of generalized vitiligo with anti-TNF-α agents. J Drugs Dermatol. 2012;11(4):534–539.22453596[PubMed: ]16Whitton ME Pinart M Batchelor J et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2010;(1):CD003263.17Hofer A Hassan AS Legat FJ et al. Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. Br J Dermatol. 2005;152(5):981–985.15888156[PubMed: ]18Viles J Monte D Gawkrodger DJ. Vitiligo. BMJ. 2010;341:c3780.19Horev A Weintraub AY Sergienko R et al. Pregnancy outcome in women with vitiligo. Int J Dermatol. 2011;50(9):1083–1085.22126869[PubMed: ] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesspediatrics.mhmedical.com/content.aspx?aid=1114877802 ER -